Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Tuesday, September 30, 2025.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2025 (2025-09-30): -675.51%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-309.38%
RETURN ON EQUITY (ROE) AVG 3Y
-366.82%
RETURN ON EQUITY (ROE) AVG 5Y
-181.35%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Vivos Therapeutics, Inc.
Market Cap
$2.14M
Return on Equity (ROE)
N/A
TTM Avg
-309.38%
3Y Avg
-366.82%
5Y Avg
-181.35%
Market Cap
$2.13M
Return on Equity (ROE)
-1160.10%
TTM Avg
-528.10%
3Y Avg
-389.86%
5Y Avg
-336.02%
Market Cap
$2.32M
Return on Equity (ROE)
-69.79%
TTM Avg
-83.20%
3Y Avg
-70.37%
5Y Avg
-0.36%
Market Cap
$2.37M
Return on Equity (ROE)
-391.26%
TTM Avg
-355.49%
3Y Avg
-474.62%
5Y Avg
-295.97%
Market Cap
$2.37M
Return on Equity (ROE)
-75.70%
TTM Avg
-349.85%
3Y Avg
-22.96%
5Y Avg
-60.31%
Market Cap
$2.38M
Return on Equity (ROE)
-53.49%
TTM Avg
-904.74%
3Y Avg
-509.27%
5Y Avg
-319.78%
Market Cap
$2.38M
Return on Equity (ROE)
-261.73%
TTM Avg
-293.81%
3Y Avg
-189.35%
5Y Avg
-145.76%
Market Cap
$1.88M
Return on Equity (ROE)
-509.36%
TTM Avg
-212.22%
3Y Avg
-233.92%
5Y Avg
-323.18%
Market Cap
$1.88M
Return on Equity (ROE)
-30.92%
TTM Avg
247.31%
3Y Avg
-294.42%
5Y Avg
-190.41%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vivos Therapeutics, Inc. (VVOS) | $2.14M | N/A | -309.38% | -366.82% | -181.35% |
| GeoVax Labs, Inc. (GOVX)vs › | $2.13M | -1160.10% | -528.10% | -389.86% | -336.02% |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | -69.79% | -83.20% | -70.37% | -0.36% |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.37M | -391.26% | -355.49% | -474.62% | -295.97% |
| Onconetix, Inc. (ONCO)vs › | $2.37M | -75.70% | -349.85% | -22.96% | -60.31% |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.38M | -53.49% | -904.74% | -509.27% | -319.78% |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.38M | -261.73% | -293.81% | -189.35% | -145.76% |
| Autonomix Medical, Inc. (AMIX)vs › | $1.88M | -509.36% | -212.22% | -233.92% | -323.18% |
| TransCode Therapeutics, Inc. (RNAZ)vs › | $1.88M | -30.92% | 247.31% | -294.42% | -190.41% |
| Tenon Medical, Inc. (TNON)vs › | $1.84M | N/A | -239.06% | -695.85% | -455.08% |
ROE
N/A
ROA
-106.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-09-30 | -675.51% |
| 2025-06-30 | -312.46% |
| 2025-03-31 | -254.98% |
| 2024-12-31 | -140.01% |
| 2024-09-30 | -163.97% |
| 2024-06-30 | -189.77% |
| 2023-06-30 | -890.50% |
| 2023-03-31 | -289.12% |
| 2022-12-31 | -496.69% |
| 2022-09-30 | -255.20% |
| 2022-06-30 | -169.61% |
| 2022-03-31 | -106.54% |
| 2021-12-31 | -79.44% |
| 2021-09-30 | -58.96% |
| 2021-06-30 | -42.50% |
| 2021-03-31 | -89.78% |
| 2020-12-31 | -71.27% |
